PARP inhibitors are well-known for generating synthetic lethality in BRCA-mutant breast and ovarian cancer cells, which is largely attributed to a deficiency in homologous recombination (HR) [37–40]. The gene discussed is PARP1; the disease is ovarian carcinoma.